Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cynarine is a naturally occurring **small molecule phenolic compound** isolated from artichoke and best known chemically as **1,3-dicaffeoylquinic acid**. It is not a modern proprietary pipeline asset from a single biotech developer, but rather a plant-derived bioactive that has appeared in historical pharmaceutical products and remains available as a research chemical and as a constituent of artichoke-based nutraceutical preparations. Reported activities include **cholagogue and choleretic effects** that promote bile secretion, along with antioxidant, hepatoprotective, antihistaminic, antiviral, and antilipemic properties. Mechanistic literature cited in the provided context indicates effects on **CD28 of T-cell receptors**, induction of **Nrf2 nuclear translocation**, restoration of glutathione and reactive oxygen species balance, and inhibition of mitochondrial depolarization. It has been investigated or used in contexts such as digestive disorders, hypercholesterolemia, and non-alcoholic fatty liver disease, although evidence is heterogeneous and cynarine is better characterized as a natural product and nutraceutical ingredient than as a currently developed prescription pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cynarine.